A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state

PURPOSE: To evaluate the safety, pharmacokinetics and determine the recommended dose of the selective apoptotic antineoplastic drug, OSI-461 administered on a twice-daily regimen to patients with advanced solid malignancies. METHODS: In this phase I trial, 33 patients were treated with OSI-461 doses...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: O’Bryant, C. L., Lieu, C. H., Leong, S., Boinpally, R., Basche, M., Gore, L., Leonardi, K., Schultz, M. K., Hariharan, S., Chow, L., Diab, S., Gibbs, A., Eckhardt, S. G.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2008
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2814254/
https://ncbi.nlm.nih.gov/pubmed/18509645
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-008-0761-3
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge